Table 3.
Intervention related changes in fasting serum parameters of glucose metabolism of MCI patients dependent on group and time.
| Resveratrol (n = 18) | Placebo (n = 22) | |||||||
|---|---|---|---|---|---|---|---|---|
| BL | FU | p-value | BL | FU | p-value | Unadjusted p-value (group × time)c | Adjusted p-value (group × time)d | |
| HbA1c [%]e | 5.86±0.36 | 5.71±0.33 | 0.005a | 5.73±0.29 | 5.71±0.28 | 0.769b | 0.059 | 0.066 |
| Glucose [mg/dl]f | 97.6±13.1 | 101.8±25.0 | 0.392a | 96.7±15.2 | 97.2±15.1 | 0.807b | 0.468 | 0.297 |
| Insulin [mU] | 8.7±3.7 | 10.4±12.6 | 0.349b | 9.2±4.1 | 9.0±5.8 | 0.163b | 0.521 | 0.402 |
Data expressed as mean ± SD. Significant results are highlighted in bold (p < 0.05). BL, baseline; FU, follow-up; HbA1c, glycated hemoglobin A1c.
a
Paired t-test.
b
Wilcoxon signed-rank test.
c
ANOVARM, unadjusted.
d
ANCOVARM, adjusted for age, sex, APOE e4 status and education.
e
Three subject excluded due to missing values (placebo group).
f
One subject excluded due to missing values (placebo group).